GlobeNewsWire
01 Oct 2026, 23:30 UTC · 19h ago
Verdict
Headline takes no side. We score CGEM +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Cullinan Therapeutics has initiated an NDA submission for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC under the FDA's Real-Time Oncology Review program.
Newpress release dated Oct 01, 2026
So whatCompletion of the full filing by year-end 2026 shifts the approval timeline forward via the RTOR's accelerated data review process.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Cullinan is eligible for milestone payments of $100 million upon first-line and $30 million upon second-line U.S. regulatory approvals for zipalertinib.
Priced ingeneral company terms cited in press release
So whatA combined $130 million in potential milestones provides a significant non-dilutive cash infusion to fund its T cell engager pipeline.
More positive than 87% of claims this week
The FDA has a PDUFA target action date of February 27, 2027, for the zipalertinib monotherapy NDA seeking accelerated approval in the second-line setting.
Priced inPDUFA date cited as existing
So whatThis creates a binary catalyst event in Q1 2027 that will likely precede the first-line decision.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company has initiated an NDA submission for zipalertinib based on positive Phase 3 trial results and is eligible for significant milestone payments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
54m ago
+2.4%
Price agrees with the score
$14.87 vs $14.53 close before publication (Oct 1) · not market-adjusted
CGEM chart →
